Abstract
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. The majority of patients present with incurable disease and will require systemic therapy; however, the development of targeted therapies has been limited by a lack of tissue. As the number of HCC biopsies performed for research in this context increases, there is an increasing need to optimize biopsy quality. Here, we present biopsy quality outcomes from a prospective observational clinical trial profiling HCC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
